(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 04 February 2016
Thank you for submitting your manuscript to us. Again, I am very sorry for the delay in getting back to you. As you know the delay is due to the fact that the referees, who previously refereed your manuscript at another journal, needed to give their consent for revealing their identities to The EMBO Journal and to allow re-use of their previous reports for further evaluation here.
Two of the original three referees (#1, autophagy expert; and #3, immunology/cell death expert) have now reviewed the current version of your manuscript. They thus cover the relevant expertise required to fully assess your work. Both referees comment on whether in their view the previous critiques were adequately addressed and whether the work warrants further consideration at The EMBO Journal.
As you will see in the reports below, referee #3 is satisfied with the revision and supports publication here. However, referee #1 still finds that the data on autophagy/mitophagy are not sufficiently developed to support the proposed downregulation of autophagy during AICD. This referee finds that further work is needed to conclusively support the reported claims. Referee #1 also outlines what kind of assays are needed to strengthen the analysis. In light of the remaining concerns raised by referee #1 and in order to reach a balanced and fair decision, I decided to involve an additional autophagy/immunology expert. The additional expert is in agreement with the issues raised by referee #1 and finds that they would need to be resolved for consideration here. One exception is the EM data, which in the advisor's view are of sufficient quality and might simply need re-interpretation of autophagosomes versus autolysosomes. I realize that addressing the remaining issues outlined by referee #1 will require additional work. The proposed experiments should however be doable, including the proposed atg5 cellular KO experiments, and this is the level of analysis needed for further consideration here. Should you be able to extend the analysis along the lines indicated, I would like to invite you to submit a suitably revised manuscript for our consideration. You can use the link below to upload the revised version. Please let me know if we need to discuss anything further.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
REFEREE REPORTS

Referee #1:
Although some of the previous concerns have been clarified, this manuscript continues to have critical concerns regarding the quantitative evaluation of the mitophagic activity. It is still unclear how much damaged mitochondria accumulate during AICD and how much of them are degraded if autophagy is activated pharmacologically (by rapamycin) or genetically (by expression of the AMPK S173A-S485/491A mutant) to protect AICD. According to the data presented in Fig. 6 , the change in mitochondrial contents upon rapamycin treatment seems to be modest. Nonetheless, it is sufficient to protect cell death (Fig. 5b) . Furthermore, the involvement of autophagy is not directly investigated using ATG knockout cells. It is uncertain whether the effects reported are indeed through autophagy and mitophagy.
Specific comments:
Previous comment #1 Unfortunately, the autophagy data are still not convincing. -The images shown in Fig. 1g and 1h do not sufficiently meet the criteria. The structure in Fig. 1g has only one membrane (not two membranes) and contains some dense unknown materials. The structure in Fig. 1h (2008) . The authors may retain these images, but as these cannot be strong evidence, the authors' conclusion should be supported by other solid data.
-If the authors admit that the images shown in new Fig. 3d are not appropriate, please replace them with typical ones. I am concerned that the high red background signal may be auto-fluorescence of dying cells, which mask true autophagy signals.
-It is unclear why the authors still use mCherry-LC3 and can conclude "In our case, the mCherry-LC3 puncta observed in previous Fig. 3c, now Fig. 3d , can only be interpreted as autophagosomes or, in a few cases, as autophagolysosomes" in the rebuttal letter. As this reviewer pointed out, mCherry-LC3 usually accumulates in lysosomes. The authors should exclude this possibility experimentally, for example by co-staining with lysosome markers. -In new Fig. 6 , there remains no evidence that mitochondria are indeed degraded by autophagy. Knockout or knockdown of ATGs is required.
Previous comment #4 Again, there is only a little evidence that dysfunctional mitochondria are eliminated by autophagy. - Fig. 3a : As mitochondria are not clear, it is hard to evaluate colocalization between Parkin and mitochondria (Fig. 3b ).
- Fig. 3c : Colocalization between LC3 and Parkin does not necessarily indicate mitochondrial degradation. The data shows that the lysosomal inhibitors cause an increase in the LC3-Parkin colocalization rate, which means that Parkin-positive mitochondria are degraded in the lysosome during AICD. This is contradictory to the authors' hypothesis. Furthermore, the effect of the lysosomal inhibitors on this colocalization rate is not changed by rapamycin treatment (Fig. 6e) , suggesting that rapamycin does not induce mitophagy and its AICD-protective effect is mitophagy (lysosome)-independent.
- Fig. 6c : The data suggest that elimination of a very small fraction (10-20%?) of mitochondria can rescue cell death. This is not easy to believe. The authors should carefully estimate how much mitochondria are degraded by rapamycin-induced autophagy reactivation to inhibit AICD. If autophagy is blocked by using ATG knockout or knockdown cells, these cells cannot be rescued by rapamycin treatment? - Fig. 4 : Similarly, how much mitochondria are degraded if AMPK S173A-S485/491A is expressed is not determined. This is also important to evaluate the magnitude of mitophagy required for AICD protection.
Previous comment #7
This reviewer does not think that the authors successfully show a defect in autophagic flux in Ambra+/-cells. Why are heterozygous mutant cells used? The quality of this paper cannot be improved by including ambiguous in vivo data. Use of some homozygous ATG mutant cells in culture would give a clearer result.
Referee #3:
The authors have sufficiently addressed my previous concerns and the revised manuscript is improved. We thank the Reviewer for the suggestion. For this aspect we thus followed the Editor's, the Referee's and the additional expert's indications and retained them, although re-interpreting and softening our definition of autophagosomes/autophagolysosomes, in the text and corresponding legend of the manuscript. Indeed, as mentioned above, we generically termed these structures "autophagic structures" and, although still keeping the simpler indication of Ay tagging the images, we specified in the figure legend 1g,h that the indicated structures "might be late autophagosomes or most likely autophagolysosomes". Also in this case, we thank the Reviewer for her/his appropriate comment. We now include here below an IF experiment (performed at the same time point of the EM images) by which we show the lack of co-localization between mCherry-LC3 and the lysosomal marker Lamp1 in AICD conditions. The unstimulated control cell instead shows a partial co-localization of the two proteins. This result neither is surprising nor it contradicts the EM images. Indeed, the IF experiment demonstrates that in basal autophagy some puncta correspond to the autophagolysosomal/lysosomal phase. By contrast, figures 1h,g show single autophagic structures, the identity of which remains inevitably undefined.
mCherry-LC3 and LAMP1 do not colocalize at the experimental conditions of Fig 3d.
hPB Ts were transfected with mCherry-LC3 and treated as indicated. 30min after AICD induction cells were fixed and stained with LAMP1 antibody and DAPI. Here are shown representative images of control and AICD treated cells.
-In new Fig. 6, there remains no evidence that mitochondria are indeed degraded by autophagy. Knockout or knockdown of ATGs is required.
We are extremely thankful to the Reviewer for her/his precious suggestion to perform and confirm crucial results by means of knocking-down ATGs in our system and model, in this and other contexts of the work. This allowed us to definitely strengthen our data, thus making the work message much more robust. Indeed, in agreement with the Reviewer suggestion, we performed AICD experiments in Atg7 KD and KO cells and, in the specific context highlighted by the Reviewer, we confirmed the effective dependence on the autophagic machinery for the restoration of mitochondria removal upon Rapamycin treatment during AICD. Indeed, in Atg7 KD cells (by siRNA) and Atg7 KO cells, the recovery of damaged mitochondria removal normally obtained with Rapamycin treatment was reduced or ineffective, respectively. These data are now shown in the new Fig 7 of the revised manuscript. Further, we also show, in Fig 7d, that Rapamycin did not succeed on rescuing the correct mitochondria membrane potential in Atg7-interfered cells during AICD. Most likely, the only partial effect in Atg7 KD cells is due to the only partial (68%) reduction of protein levels 48h upon double siRNA transfection. Of note, we chose to modulate Atg7 for the following reasons: i) we had the possibility to easily and quickly obtain also conditional KO mice for this Atg protein (to strongly improve our data) and ii) Atg7 is probably the most suitable autophagic and Atg protein, among others, to interfere with in order to obtain a strong inhibition of the autophagic pathway.
Previous comment #4
Again, there is only a little evidence that dysfunctional mitochondria are eliminated by autophagy.
- Fig. 3a : As mitochondria are not clear, it is hard to evaluate colocalization between Parkin and mitochondria (Fig. 3b) .
We thank the Reviewer for noticing this weakness. The previous AICD-treated cell image in Fig. 3a has been substituted by a new one, in which the mitochondrial structure is much clearer, and the data on Parkin translocation in Fig 3b are consequently more robust.
- Fig. 3c We thank the Reviewer for this important comment that, admittedly, needed clarification. The uncoupling between Parkin recruitment to mitochondria and their effective clearance, lacking during AICD due to macroautophagy inhibition, is one of the central messages of our paper. Indeed, by comparing the AICD condition with the corresponding untreated control condition, regardless of the autophagy flux block, we observe a significant reduction of the number of LC3+Parkin doublepositive dots in Parkin-dotted cells, independently of the lysosomal activity.
However, admittedly, in the previous version of the paper, the comparison between blocked/unblocked autophagic flux within the same experimental condition was suggesting that, during AICD, autophagy was active and able to remove damaged mitochondria. In this case, thanks to the Reviewer comment, we realized and admit that we performed a wrong analysis, for at least two reasons: 1) the block of lysosomal degradation was irrelevant in this very experiment for the purpose to unravel an ineffective removal of damaged Parkin-decorated mitochondria through macroautophagy during AICD, unless upon Rapamycin treatment.
2), and most important, we erroneously restricted our analysis only to Parkin-positive cells, and we considered the fluorescence (thus the dot number) from only one focal plane of each cell. This has been a key error, since T cells are small, round cells with a relatively small amount of LC3 dots (less then 20), already under the strongest pro-autophagic conditions. Instead, it would have been correct to analyse the whole cell volume in order to avoid overestimation of the autophagy activity. Primed by this important reconsideration of our analysis, we thus repeated it by expanding it to the Parkin-negative cells and by considering the number of dots per each cell in its Z-stack 3D reconstruction. By this new analysis without changing anything in the experimental conditions, we could, indeed, detect a significant increase in the number of colocalizing LC3-Parkin dots during AICD, in the presence of both lysosomal inhibitors and Rapamycin treatment, when compared to the same condition but without inhibitors. By contrast, during AICD in the absence of Rapamycin, the amount of LC3-Parkin dots remained the same, also upon lysosomal inhibition.
The new analysis is now reported in Fig 3c and in Fig 6e of the revised manuscript.
Furthermore, in order to appreciate our data, we believe that the right comparison, when considering an LC3-Parkin co-localization on mitochondria, should be done between conditions with the same mitochondrial "health status": Parkin increases its translocation (i.e. dots number) to mitochondria when they are damaged. This condition should be analysed by comparing the AICD-stimulated Rapamycin-treated results with the AICD-stimulated Rapamycin-untreated ones, where in both cases AICD induces mitochondria depolarization. Conversely, the unstimulated Rapamycin-treated condition should be compared with the unstimulated Rapamycin-untreated condition, where mitochondria are healthy and there is no reason for Parkin to translocate to the organelle. The same is true regardless the lysosomal degradation block. In all cases, our results are now perfectly fitting with our hypothesis and main message of the work.
In the revised manuscript we replaced only the existing histogram, showing the number of LC3-Parkin positive dots per cell. For completeness, we decided to show here below also the revised analysis for the LC3 and Parkin single dots amount, per cell and per condition. Also in these graphs, all results are expected and fitting with our hypothesis. The fact, for example, that we appreciate a slightly reduced autophagic activity (LC3 single dots) in the Rapamycin+AICD condition compared with the Rapamycin unstimulated condition, is simply explained by the consideration that Rapamycin-induced autophagy restoration has anyway to compete with the AICD-induced block of the same machinery, although acting through two alternative but not completely independent pathways. Finally, the reader should take into account that this very experiment is performed in double-transfected (for both LC3 and Parkin) cells, this implying that basal autophagy could be slightly higher due to over-expression of Parkin, capable to induce autophagy per se (see Burbulla LF et al, 2014; Khandelwal PJ et al, 2011).
Autophagy/mitophagy measured during AICD, indicated as number of dots per cell.
Jurkat cells were transfected with GFP-LC3 and Parkin-Cherry, treated as indicated, fixed 24h after AICD induction and immuno-stained with anti-TOM20 antibody. Z-stacks covering the entire volume of the cells were acquired in the three channels referred to GFP, Parkin and TOM20. Quantification of number of LC3 dots, Parkin dots and LC3/Parkin colocalizing dots on mitochondria was then performed going through the single stacks. Data represent mean ± SE of three independent experiments.
-Fig. 6c: The data suggest that elimination of a very small fraction (10-20%?) of mitochondria can rescue cell death. This is not easy to believe. The authors should carefully estimate how much mitochondria are degraded by rapamycin-induced autophagy reactivation to inhibit AICD. If autophagy is blocked by using ATG knockout or knockdown cells, these cells cannot be rescued by rapamycin treatment?
We thank the Reviewer for this comment that allows us to clarify this point. Data in Fig 6c demonstrate a Rapamycin-dependent rescue of mitochondria clearance of around 30% for Tom20 and 45% for MnSOD 24h upon AICD induction. In the case of MnSOD, the mitochondria levels at 24h and 32h upon AICD with Rapamycin treatment are brought back to the same levels of the control initial values, this being equivalent to the 4h upon AICD condition, where no organelle accumulation is detected yet. Further, this rapamycin rescue effect is confirmed by data in Fig EV5  D (data already present in the previous version of the manuscript and figure previously named Fig  S8b) , obtained by measuring the mean fluorescence intensity of MitoTraker Green, which is modulated independently of individual mitochondrial protein levels. We believe that this difference might be sufficient for the cell death rescue and we are sure the Reviewer, given this clarification, will share our view. Moreover, and even more interestingly, the new results shown in Fig 7b of the revised manuscript clearly show that Rapamycin treatment during AICD is not able to rescue the viability of Atg7 KO cells, and only partially that of KD cells (Fig 7c) .
- Fig. 4 : Similarly, how much mitochondria are degraded if AMPK S173A-S485/491A is expressed is not determined. This is also important to evaluate the magnitude of mitophagy required for AICD protection.
The Reviewer raises an important point regarding the investigation of mitochondria degradation when autophagy is genetically inhibited on the specific pathway involved in AICD modulation. We thank her/him for the insightful suggestions. In this revised version of the paper we have performed and included experiments measuring the levels of mitochondrial markers during AICD, in cells overexpressing the AMPKS173A-S485/491A mutant (Fig. EV4 d,e in the new version of the manuscript; two new panels added to the previous S6 figure) . As the Reviewer will appreciate, when AMPK is constitutively active, we have more than 40% recovery of mitochondria clearance for MnSOD and 20% for Tom20, results that strengthen again the magnitude of mitochondria removal through functional autophagy for AICD protection.
Previous comment #7
Ctrl Ctrl AICD AICD 0 
This Reviewer does not think that the authors successfully show a defect in autophagic flux in Ambra+/-cells. Why are heterozygous mutant cells used? The quality of this paper cannot be improved by including ambiguous in vivo data. Use of some homozygous ATG mutant cells in culture would give a clearer result.
We thank the Reviewer for this comment that allows us to clarify this point and to strengthen our data in vivo. This deeply increased the quality of our work. Originally, we used Ambra1-depleted heterozygous cells because the homozygous mice are embryonically lethal (Fimia et al., 2007) , and it was thus impossible obtaining mature T cells from these mice. Nevertheless, we followed the precious suggestion of the Reviewer and performed the same experiment with Atg7 KO and KD cells, as previously mentioned. The new Fig 7b,c of the revised manuscript, clearly shows that T cells are more sensitive to AICD in ATG-mutated cells, and their viability is not significantly rescued by Rapamycin.
• Thank you for submitting your revised manuscript for our consideration. Your manuscript has now been seen once more by one of the original referees (see comments below), and as you will see the referee appreciates the introduced changes. I am thus happy to inform you that your manuscript has been accepted in principle for publication in The EMBO Journal. Congratulations!
REFEREE REPORT
Referee #1:
For animal studies, include a statement about randomization even if no randomization was used. Is there an estimate of variation within each group of data?
Is the variance similar between the groups that are being statistically compared?
6. To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile. e.g., Antibodypedia (see link list at top right), 1DegreeBio (see link list at top right).
In every legends N, Mean and S.E.M. are indicated. P--value is also explicitly indicated.
In figures t test was used as Shapiro--Wilk test and confirmed normal distribution. Power was calculated as described above.
For each experiment, power analysis included an estimate of variance based on our experimental experience, see formula above.
Variance is similar. 
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND 
We verified that the sample was following normal distribution by Shapiro--Wilk test. Power was calculated using the following: n=3 (za + zb)2 (s/D)2 n=analyzed samples a=0,05 (P, predetermined) za = 1,96 e planned a study of a continuous response variable from matched pairs of study subjects. Prior data indicate that the difference in the response of matched pairs is normally distributed with 5% standard deviation. Then, if the true difference in the mean response of matched pairs was 10%, we would need to study 4 pairs of subjects to be able to reject the null hypothesis that this response difference was zero with probability (power) 80%. The Type I error probability associated with this test of this null hypothesis was 0,05.
No inclusion/exclusion criteria were applied
No randomization, or similar procedure, was used.
The animal experiments were randomized since there was no criterion of animal selection/allocation to experimental groups except for the identification of the correct genotype required by the experiment.
The experimenter were blinded to the genotype of the animals during experiment and data analysis. Image analysis was performed blind to the treatment conditions (section: online methods --paragraph: Imaging)
The experimenters were blinded to the genotype of the animals during experiment and data analysis.
definitions of statistical methods and measures:
Journal Submitted to: THE EMBO JOURNAL Corresponding Author Name: SILVIA CAMPELLO C--Reagents
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified
Please fill out these boxes  (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation.
a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects. This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. These guidelines are consistent with the Principles and Guidelines for Reporting Preclinical Research issued by the NIH in 2014. Please follow the journal's authorship guidelines in preparing your manuscript.
